On September 13, 2021 NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, reported that new data from a Phase 1/2 study evaluating the company’s lead asset NT-I7 (efineptakin alfa) will be presented during oral abstract sessions at the Society for Neuro-Oncology (SNO) annual meeting, to be held in Boston, Massachusetts on November 18-21, 2021 (Press release, NeoImmuneTech, SEP 13, 2021, View Source [SID1234587629]). The study evaluates the safety and efficacy of NT-I7, a novel long-acting human IL-7, given concurrently with adjuvant chemotherapy in patients with high-grade gliomas.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the oral abstract presentation are as follows:
Title: A phase I/II study evaluating the safety and efficacy of a novel long-acting interleukin-7, NT-I7, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy
Lead Author: Jian Li Campian, M.D., Ph.D., Washington University School of Medicine – St. Louis
Abstract Number: CTIM-07
Session Title: Abstract Session: Clinical Trials I
Presentation Time: November 19, 2021, 4:55pm-5:00pm ET
About NT-I7
NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed for oncologic and immunologic indications, in which T cell amplification and enhanced functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). In clinical trials to date, NT-I7 has exhibited favorable PK/PD and safety profiles, both as a monotherapy and in combination with other anticancer treatments. NT-I7 is being studied in multiple clinical trials in solid tumors and as a vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.